Dimetotiazine: Difference between revisions
Gerald Chi (talk | contribs) mNo edit summary |
Kiran Singh (talk | contribs) No edit summary |
||
(2 intermediate revisions by one other user not shown) | |||
Line 1: | Line 1: | ||
{{Drugbox | {{Drugbox | ||
| Verifiedfields = changed | | Verifiedfields = changed | ||
Line 5: | Line 4: | ||
| IUPAC_name = 10-(2-dimethylaminopropyl)-N,N-dimethylphenothiazine-2-sulfonamide | | IUPAC_name = 10-(2-dimethylaminopropyl)-N,N-dimethylphenothiazine-2-sulfonamide | ||
| image = Dimetotiazine.png | | image = Dimetotiazine.png | ||
<!--Clinical data--> | <!--Clinical data--> | ||
| tradename = | | tradename = | ||
Line 18: | Line 16: | ||
| legal_status = Rx-only | | legal_status = Rx-only | ||
| routes_of_administration = Oral | | routes_of_administration = Oral | ||
<!--Pharmacokinetic data--> | <!--Pharmacokinetic data--> | ||
| bioavailability = | | bioavailability = | ||
Line 25: | Line 22: | ||
| elimination_half-life = | | elimination_half-life = | ||
| excretion = | | excretion = | ||
<!--Identifiers--> | <!--Identifiers--> | ||
| CAS_number_Ref = {{cascite|correct|??}} | | CAS_number_Ref = {{cascite|correct|??}} | ||
Line 47: | Line 43: | ||
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}} | | StdInChIKey_Ref = {{stdinchicite|changed|chemspider}} | ||
| StdInChIKey = VWNWVCJGUMZDIU-UHFFFAOYSA-N | | StdInChIKey = VWNWVCJGUMZDIU-UHFFFAOYSA-N | ||
<!--Chemical data--> | <!--Chemical data--> | ||
| chemical_formula = | | chemical_formula = | ||
Line 55: | Line 50: | ||
}} | }} | ||
__NOTOC__ | __NOTOC__ | ||
{{ | {{SI}} | ||
{{CMG}} | |||
==Overview== | |||
'''''For patient information, click [[Oxetoron (patient information)|here]]'''''. | '''''For patient information, click [[Oxetoron (patient information)|here]]'''''. | ||
Line 63: | Line 60: | ||
'''Dimetotiazine''' ([[International Nonproprietary Name|INN]]) is a [[phenothiazine]]. It is a [[serotonin antagonist]] and [[histamine antagonist]].<ref name="pmid8564192">{{cite journal |author=Shimazawa M, Hara H, Watano T, Sukamoto T |title=Effects of Ca2+ channel blockers on cortical hypoperfusion and expression of c-Fos-like immunoreactivity after cortical spreading depression in rats |journal=Br. J. Pharmacol. |volume=115 |issue=8 |pages=1359–68 |date=August 1995 |pmid=8564192 |pmc=1908864 |doi= |url=}}</ref> | '''Dimetotiazine''' ([[International Nonproprietary Name|INN]]) is a [[phenothiazine]]. It is a [[serotonin antagonist]] and [[histamine antagonist]].<ref name="pmid8564192">{{cite journal |author=Shimazawa M, Hara H, Watano T, Sukamoto T |title=Effects of Ca2+ channel blockers on cortical hypoperfusion and expression of c-Fos-like immunoreactivity after cortical spreading depression in rats |journal=Br. J. Pharmacol. |volume=115 |issue=8 |pages=1359–68 |date=August 1995 |pmid=8564192 |pmc=1908864 |doi= |url=}}</ref> | ||
Dimetotiazine is also known as Dimétotiazine, Dimetotiazine Mesilate and Fonazine Mesylate. | |||
Dimetotiazine is also known as | |||
==Category== | ==Category== | ||
Antimigraine Drugs | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{Antimigraine preparations}} | {{Antimigraine preparations}} | ||
[[Category:Phenothiazines]] | |||
[[Category:Antimigraine drugs]] | [[Category:Antimigraine drugs]] | ||
[[Category:Drugs]] | [[Category:Drugs]] |
Latest revision as of 16:49, 14 April 2015
![]() | |
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Pregnancy category |
|
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C19H25N3O2S2 |
Molar mass | 391.55 g/mol |
3D model (JSmol) | |
| |
| |
|
WikiDoc Resources for Dimetotiazine |
Articles |
---|
Most recent articles on Dimetotiazine Most cited articles on Dimetotiazine |
Media |
Powerpoint slides on Dimetotiazine |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Dimetotiazine at Clinical Trials.gov Trial results on Dimetotiazine Clinical Trials on Dimetotiazine at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Dimetotiazine NICE Guidance on Dimetotiazine
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Dimetotiazine Discussion groups on Dimetotiazine Patient Handouts on Dimetotiazine Directions to Hospitals Treating Dimetotiazine Risk calculators and risk factors for Dimetotiazine
|
Healthcare Provider Resources |
Causes & Risk Factors for Dimetotiazine |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
For patient information, click here.
Overview
Dimetotiazine (INN) is a phenothiazine. It is a serotonin antagonist and histamine antagonist.[1]
Dimetotiazine is also known as Dimétotiazine, Dimetotiazine Mesilate and Fonazine Mesylate.
Category
Antimigraine Drugs
References
- Pages with script errors
- CS1 maint: Multiple names: authors list
- Template:drugs.com link with non-standard subpage
- Drugs with non-standard pregnancy category
- Drugs with non-standard legal status
- Articles with changed ChemSpider identifier
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles with changed InChI identifier
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Drugboxes which contain changes to verified fields
- Phenothiazines
- Antimigraine drugs
- Drugs